Capsida Biotherapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.capsida.com
Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease
Phase 1
Recruiting
- Conditions
- GBA1 Parkinson Disease
- Interventions
- Drug: gene therapy
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Capsida Biotherapeutics, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT07011771
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy
Phase 1
Recruiting
- Conditions
- Developmental and Epileptic Encephalopathy
- Interventions
- Drug: gene therapy
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Capsida Biotherapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06983158
- Locations
- 🇺🇸
Colorado Child Health Research Institute, Aurora, Colorado, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
🇺🇸Buerger Center for Advanced Pediatric Care, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Natural History Study in Pediatric Patients with STXBP1 Encephalopathy with Epilepsy
Withdrawn
- Conditions
- STXBP1 Encephalopathy with Epilepsy
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Capsida Biotherapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05462054
News
No news found